<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39443853</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>COVID-19 severity and corticosteroid treatment have minimal effect on specific antibody production.</ArticleTitle><Pagination><StartPage>1197</StartPage><MedlinePgn>1197</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1197</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-10090-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dexamethasone is currently administered for Coronavirus disease 2019(COVID-19); however, there are concerns about its effect on specific antibodies' production. The aim of this study was to evaluate whether specific antibodies were affected by COVID-19 severity and corticosteroid treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Of 251 confirmed COVID-19 patients admitted to our hospital between January 26 and August 10, 2020, the early period of the pandemic, 75 patients with sera within 1 month of onset and 1 month or longer were included in the research. A total of 253 serum samples from these patients were collected. The levels of specific antibodies for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), immunoglobulin G (IgG) and M (IgM), were measured retrospectively. The results were compared separately of each COVID-19 severity, and with or without corticosteroid treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 75 patients, 47, 18, and 10 had mild, moderate, and severe disease, respectively. The median age was 53.0 years and 22 (29%) were women. The most common comorbidities were hypertension and dyslipidemia. Corticosteroids were administered to 20 (27%) and 10 (53%), patients with moderate and severe disease, respectively. The positivity rates IgM increased first, and IgG was almost always positive after day 16, regardless of the severity of COVID-19. On days 6-10, both IgG and IgM positivity rates were higher in patients with moderate disease than in those with mild or severe disease. In patients with moderate disease, IgG positivity was similar over time, regardless of corticosteroid treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In COVID-19 patients, specific IgG is positive and maintained for a long period of time, even after corticosteroid treatment. The effect of corticosteroid treatment in a COVID-19 epidemiological study using specific IgG antibodies was considered minor. COVID-19 patients were more likely to receive oxygen if IgM was positive 1 week after onset, but not mechanical ventilation. IgM measurement 1 week after onset may predict COVID-19 severity.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamoto</LastName><ForeName>Takato</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan. tnakamoto@hosp.ncgm.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwamoto</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oshiro</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inamura</LastName><ForeName>Natsumi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemoto</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ide</LastName><ForeName>Satohi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Keiji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for the Study fo Global IInfection, Kushu University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomoto</LastName><ForeName>Hidetoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>Yutaro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazato</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Michiyo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kumiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Moto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Sho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutsuna</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection Control, Graduate School of Medicine / Faculty of Medicine, Osaka University, Suita City, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmagari</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP20fk0108262h001</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="Y">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="Y">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Corticosteroids</Keyword><Keyword MajorTopicYN="N">Severity</Keyword><Keyword MajorTopicYN="N">Specific antibody</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>0</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39443853</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-10090-z</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-10090-z</ArticleId><ArticleId IdType="pmc">PMC11515524</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections - the state of the art. Emerg Microbes Infect. 2020;9:747–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172701</ArticleId><ArticleId IdType="pubmed">32196430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic testing for severe acute respiratory syndrome-related coronavirus 2: A narrative review. Ann Intern Med. 2020;172:726–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170415</ArticleId><ArticleId IdType="pubmed">32282894</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillary VE, Ceasar SA. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon. 2023;9: e13952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9946785</ArticleId><ArticleId IdType="pubmed">36855648</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID-19. Interim guidelines for COVID-19 antibody testing, https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing/antibody-tests-guidelines.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Flab%2Fresources%2Fantibody-tests.html. Accessed 19 Feb 2024.
</Citation></Reference><Reference><Citation>To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158907</ArticleId><ArticleId IdType="pubmed">32213337</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos H, Trougakos IP, Dimopoulos MA, Terpos E. Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies. Eur J Intern Med. 2023;107:7–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9647045</ArticleId><ArticleId IdType="pubmed">36379820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kritikos A, Gabellon S, Pagani JL, Monti M, Bochud PY, Manuel O, et al. Anti-SARS-CoV-2 titers predict the severity of COVID-19. Viruses. 2022;14(5): 1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9143418</ArticleId><ArticleId IdType="pubmed">35632830</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693–704.</Citation></Reference><Reference><Citation>Nagashima M, Kumagai R, Yoshida I, Kawakami M, Nagano M, Asakura H, et al. Characteristics of SARS-CoV-2 isolated from asymptomatic carriers in Tokyo. Jpn J Infect Dis. 2020;73:320–2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32350227</ArticleId></ArticleIdList></Reference><Reference><Citation>Interiano C, Muze S, Turner B, Gonzalez M, Rogers B, Jerris R, et al. Longitudinal evaluation of the Abbott ARCHITECT SARS-CoV-2 IgM and IgG assays in a pediatric population. Pract Lab Med. 2021;25: e00208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893289</ArticleId><ArticleId IdType="pubmed">33623814</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131:954–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17426195</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Management Guideline. Ministry of Health, Labour and Welfare. Tokyo, Japan. https://www.mhlw.go.jp/content/001248424.pdf. Accessed 23 Sept 2024.
</Citation></Reference><Reference><Citation>Settipane GA, Pudupakkam RK, McGowan JH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol. 1978;62:162–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">681628</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler WT, Rossen RD. Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone. J Clin Invest 1973;52:2629–40.</Citation></Reference><Reference><Citation>Masiá M, Fernández-González M, García JA, Padilla S, Gutiérrez F. Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19. J Infect. 2021;82:414–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7585730</ArticleId><ArticleId IdType="pubmed">33115658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH 3rd, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182:429–46.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250779</ArticleId><ArticleId IdType="pubmed">32526206</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang N, Pérez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. 2021;27(5):892–903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240394</ArticleId><ArticleId IdType="pubmed">33767405</ArticleId></ArticleIdList></Reference><Reference><Citation>Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus Disease 2019. Clin Infect Dis. 2020;71:2027–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184337</ArticleId><ArticleId IdType="pubmed">32221519</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:2255–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197626</ArticleId><ArticleId IdType="pubmed">32337590</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Yue D, Wang Y, Wang F, Wu S, Hou H. The dynamics of immune response in COVID-19 patients with different illness severity. J Med Virol. 2021;93:1070–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32910461</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse H, Lung DC, Wong SC, Ip KF, Wu TC, To KK, et al. Emergence of a severe acute respiratory syndrome coronavirus 2 virus variant with novel genomic architecture in Hong Kong. Clin Infect Dis 2021:ciab198.</Citation></Reference><Reference><Citation>Pavlidis G, Kampolis CF, Perlepe G, Pagonis A, Maniotis C, Koullias E, et al. Do the kinetics of antibody responses predict clinical outcome in hospitalized patients with moderate-to-severe COVID-19? In Vivo. 2022;36(4):1944–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9301394</ArticleId><ArticleId IdType="pubmed">35738610</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouladzadeh M, Hosseinzadeh M, Khedri R, Choghakabodi PM, Amini P, Bavani AG, et al. Investigating the diagnostic and prognostic value of anti-SARS-CoV-2 Spike IgG/IgM ELISA tests in patients infected with coronavirus Delta variant. Infez Med. 2024;32(1):25–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10917556</ArticleId><ArticleId IdType="pubmed">38456030</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkert FR, Lanser L, Bellmann-Weiler R, Weiss G. Coronavirus disease 2019: clinics, treatment, and prevention. Front Microbiol. 2021;12: 761887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631905</ArticleId><ArticleId IdType="pubmed">34858373</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>